Bizengri Disease Interactions
There are 4 disease interactions with Bizengri (zenocutuzumab).
Zenocutuzumab (applies to Bizengri) congestive heart failure
Moderate Potential Hazard, Moderate plausibility.
Zenocutuzumab can cause left ventricular dysfunction and has not been studied in patients with a history of clinically significant cardiac disease or left ventricular ejection fraction (LVEF) less than 50% prior to treatment initiation. LVEF should be evaluated prior to using this drug and monitored at regular intervals during treatment.
Zenocutuzumab (applies to Bizengri) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The pharmacokinetics of zenocutuzumab have not been studied in patients with moderate to severe hepatic impairment (total bilirubin greater than 1.5 to 3 times upper limit of normal with any AST).
Zenocutuzumab (applies to Bizengri) pulmonary impairment
Moderate Potential Hazard, Moderate plausibility.
Zenocutuzumab can cause interstitial lung disease (ILD) and pneumonitis. New or worsening pulmonary symptoms that can indicate ILD or pneumonitis such as dyspnea, cough, or fever, should be closely monitored.
Zenocutuzumab (applies to Bizengri) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The pharmacokinetics of zenocutuzumab in patients with severe renal impairment (CrCl less than 30 mL/min) is unknown.
Switch to professional interaction data
Bizengri drug interactions
There are 95 drug interactions with Bizengri (zenocutuzumab).
Report options
More about Bizengri (zenocutuzumab)
- Bizengri consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous bispecific antibodies
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.